Expanded Fetal Focus™ Panel Coming Soon

Horizon™ Carrier Screen with Fetal Focus™

Direct fetal insights for inherited single-gene conditions from the maternal carrier’s sample

Screen the fetus for inherited conditions – no partner sample needed

Fetal Focus™ directly screens the fetus for inherited single-gene conditions, addressing challenges with standard carrier screening when reproductive partners do not complete testing.

Screen for ACOG-Recommended Genes¹: Fetal Focus™ currently screens for five genes after Horizon™ carrier screen identifies the pregnant patient as a carrier
- Cystic fibrosis (CFTR)
- Alpha-thalassemia (HBA1/HBA2)
- Spinal muscular atrophy (SMN1)
- Beta-hemoglobinopathies (HBB) including sickle cell disease
Expanded Panel Coming Soon: Fetal Focus™ will soon expand to include clinically actionable conditions where early diagnosis can help parents access FDA-approved treatments earlier and make a difference in their baby’s health

Fetal Focus™ is not currently available to order in New York state. We will provide updates when the test becomes available.

Integrate Fetal Focus™ into your carrier screening workflow with ease

*Fetal Focus™ is available with Horizon a la carte (individual orders of cystic fibrosis and spinal muscular atrophy), H4, Hbasic, H14, H27, H106, and H274

Screen for affected pregnancies across diverse populations

Fetal Focus™ is designed to address known technical limitations that can lead to false negative results, such as homozygous variant detection. In the first milestone EXPAND readout, Fetal Focus™ detected 5/5 challenging homozygous cases, including one pregnancy affected by a homozygous non-F508del cystic fibrosis variant.^2,3

†Fetal Focus™ is a screening test, not a diagnostic test. False positive and false negative results can occur. A high risk result does not mean the fetus is affected. Similarly, a low risk result does not definitively mean the fetus is unaffected. Genetic counseling and diagnostic testing should be offered to further evaluate high risk results.

John Williams, M.D.

Chief principal investigator for EXPAND and director of reproductive genetics at Cedars-Sinai

Having access to a noninvasive option like Fetal Focus™ can provide critical information to support decision-making during pregnancy, especially in situations where partner testing isn’t possible

Improved detection with the proprietary LinkedSNP™ technology

Watch how LinkedSNP^TM technology utilizes SNP markers, comprehensive NGS sequencing, and bioinformatic models to enhance detection of the disease-causing variants, regardless of ancestry

Available with the #1 ordered NIPT and carrier screen⁴

In one blood draw, your patients receive the pioneering SNP-based Panorama™ NIPT and comprehensive Horizon™ carrier screening with Fetal Focus™ as an add-on

Inform decisions about Rh immune globulin with Fetal RhD NIPT
Distinguish the viable twin from the vanished twin

Learn how Fetal Focus™ can be integrated in your practice

First Name *

Last Name *

Email Address *

Phone *

Zip Code *

Country *

I am a *

Company

Comments

Natera Honey Pot

Natera would like to send you information about our products and services. You may unsubscribe from these communications at any time. By submitting your information you are agreeing to Natera's terms of use and privacy policy.

References

¹American College of Obstetricians and Gynecologists, Committee Opinion #691, March 2017
²Internal data on file from EXPAND clinical study. In EXPAND, the study participants and investigators are blinded to the Fetal Focus™ test results.
³Expanding Prenatal Cell Free DNA Screening Across MoNogenic Disorders (EXPAND). https://clinicaltrials.gov/study/NCT06808880.Accessed July 2025.
⁴Internal analysis of Denitive Healthcare database and ancillary data. Dec 2023.